Huveaux PLC
25 August 2005
Not for release, publication or distribution in or into the United States,
Australia, Canada, Japan or any other jurisdiction if to do so would constitute
a violation of the relevant laws of such jurisdiction
For immediate release 25 August 2005
Recommended Offer by
Dresdner Kleinwort Wasserstein Limited
on behalf of
Huveaux PLC ('Huveaux') for
Epic Group plc ('Epic')
Posting of compulsory acquisition notice
Huveaux announces that as at 3.00 p.m. on 25 August 2005, valid acceptances of
the Offer had been received in respect of 21,802,647 Epic Shares, representing
approximately 90.16 per cent. of the existing issued ordinary share capital of
Epic.
As valid acceptances of the Offer have been received in respect of more than 90
per cent. in value of Epic Shares to which the Offer relates, Huveaux intends to
apply the provisions of sections 428-430F of the Companies Act 1985 to acquire
compulsorily all outstanding Epic Shares under the terms of the Offer.
Accordingly, Huveaux will be shortly posting formal notices under section 429 of
the Companies Act 1985 to Epic Shareholders who have not yet accepted the Offer.
The Offer will remain open until further notice.
As previously announced, application has been made to the London Stock Exchange
for the trading of Epic Shares on AIM to be cancelled. The cancellation of
admission will take effect on 20 September 2005.
Words and expressions defined in the Offer Document dated 28 July 2005 shall
have the same meaning when used in this announcement. Copies of the documents
posted to Epic Shareholders on 28 July 2005 are available for inspection at the
Document Viewing Facility of the UK Listing Authority at The Financial Services
Authority, 25 The North Colonnade, London E14 5HS.
Enquiries:
Huveaux 020 7245 0270
John van Kuffeler, Executive Chairman
Dresdner Kleinwort Wasserstein (Financial advisor to Huveaux) 020 7623 8000
Charles Batten
Joe Thompson
Finsbury (Public Relations advisor to Huveaux) 020 7251 3801
James Leviton
Katie Lang
Don Hunter
Dresdner Kleinwort Wasserstein, which is authorised and regulated by the
Financial Services Authority, is acting for Huveaux and for no-one else in
connection with the Offer and will not be responsible to anyone other than
Huveaux for providing the protections afforded to customers of Dresdner
Kleinwort Wasserstein, or for providing advice in relation to the Offer or any
matters referred to herein.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.